FDMT
4D Molecular Therapeutics, Inc.
Biotechnology
Market Cap$600M
5Y Perf.-74.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
FDMT vs RCKT
Revenue, margins, valuation, and 5-year total return — side by side.
RCKT
Rocket Pharmaceuticals, Inc.
Biotechnology
Market Cap$418M
5Y Perf.-93.0%
FDMT vs RCKT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FDMT | RCKT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $600M | $418M |
| Revenue (TTM) | $85M | $0.00 |
| Net Income (TTM) | $-140M | $-223M |
| Gross Margin | -14.0% | — |
| Operating Margin | -187.2% | — |
| Total Debt | $21M | $25M |
| Cash & Equiv. | $60M | $78M |
FDMT vs RCKT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FDMT
RCKT
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| 4D Molecular Therap… (FDMT) | 100 | 25.1 | -74.9% |
| Rocket Pharmaceutic… (RCKT) | 100 | 7.0 | -93.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FDMT vs RCKT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FDMT leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Rocket Pharmaceuticals, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
FDMT
4D Molecular Therapeutics, Inc.
The Long-Run Compounder
FDMT carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- -74.3% 10Y total return vs RCKT's -90.7%
- Lower volatility, beta 1.47, Low D/E 4.2%, current ratio 9.39x
- 2.3K% revenue growth vs RCKT's 10.5%
Best for: long-term compounding and sleep-well-at-night
RCKT
Rocket Pharmaceuticals, Inc.
The Income Pick
RCKT is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.31
- EPS growth 26.4%
- Beta 1.31, current ratio 6.38x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FDMT | 2.3K% revenue growth vs RCKT's 10.5% |
| Stability / Safety | RCKT | Beta 1.31 vs FDMT's 1.47 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | FDMT | +238.3% vs RCKT's -38.8% |
| Efficiency (ROA) | FDMT | -28.3% ROA vs RCKT's -67.5%, ROIC -28.1% vs -63.2% |
FDMT vs RCKT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FDMT vs RCKT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFDMTLAGGINGRCKT
RCKTRocket Pharmaceutical…
0leads
FDMT4D Molecular Therapeu…
4leads
6 Total Categories
CATEGORYLEADERvs RCKTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FDMT1/1
Valuation MetricsMultiples, price ratios, and targets
FDMT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FDMT7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
FDMT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FDMT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
FDMT and RCKT operate at a comparable scale, with $85M and $0 in trailing revenue.
| Metric | FDMT4D Molecular Ther… | RCKTRocket Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $85M | $0 |
| EBITDAEarnings before interest/tax | -$160M | -$232M |
| Net IncomeAfter-tax profit | -$140M | -$223M |
| Free Cash FlowCash after capex | -$110M | -$190M |
| Gross MarginGross profit ÷ Revenue | -14.0% | — |
| Operating MarginEBIT ÷ Revenue | -187.2% | — |
| Net MarginNet income ÷ Revenue | -164.4% | — |
| FCF MarginFCF ÷ Revenue | -129.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +85089.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +137.8% | +38.7% |
FDMT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
FDMT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | FDMT4D Molecular Ther… | RCKTRocket Pharmaceut… |
|---|---|---|
| Market CapShares × price | $600M | $418M |
| Enterprise ValueMkt cap + debt − cash | $561M | $365M |
| Trailing P/EPrice ÷ TTM EPS | -4.31x | -1.92x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 7.04x | — |
| Price / BookPrice ÷ Book value/share | 1.19x | 1.55x |
| Price / FCFMarket cap ÷ FCF | — | — |
FDMT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
FDMT leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
FDMT delivers a -31.7% return on equity — every $100 of shareholder capital generates $-32 in annual profit, vs $-80 for RCKT. FDMT carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCKT's 0.09x. On the Piotroski fundamental quality scale (0–9), FDMT scores 4/9 vs RCKT's 1/9, reflecting mixed financial health.
| Metric | FDMT4D Molecular Ther… | RCKTRocket Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -31.7% | -80.5% |
| ROA (TTM)Return on assets | -28.3% | -67.5% |
| ROICReturn on invested capital | -28.1% | -63.2% |
| ROCEReturn on capital employed | -30.3% | -58.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.04x | 0.09x |
| Net DebtTotal debt minus cash | -$39M | -$53M |
| Cash & Equiv.Liquid assets | $60M | $78M |
| Total DebtShort + long-term debt | $21M | $25M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
FDMT leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
FDMT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FDMT five years ago would be worth $3,103 today (with dividends reinvested), compared to $894 for RCKT. Over the past 12 months, FDMT leads with a +238.3% total return vs RCKT's -38.8%. The 3-year compound annual growth rate (CAGR) favors FDMT at -14.2% vs RCKT's -43.5% — a key indicator of consistent wealth creation.
| Metric | FDMT4D Molecular Ther… | RCKTRocket Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +42.3% | +11.6% |
| 1-Year ReturnPast 12 months | +238.3% | -38.8% |
| 3-Year ReturnCumulative with dividends | -36.9% | -81.9% |
| 5-Year ReturnCumulative with dividends | -69.0% | -91.1% |
| 10-Year ReturnCumulative with dividends | -74.3% | -90.7% |
| CAGR (3Y)Annualised 3-year return | -14.2% | -43.5% |
FDMT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — FDMT and RCKT each lead in 1 of 2 comparable metrics.
Risk & Volatility
RCKT is the less volatile stock with a 1.31 beta — it tends to amplify market swings less than FDMT's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FDMT currently trades 84.4% from its 52-week high vs RCKT's 49.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FDMT4D Molecular Ther… | RCKTRocket Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.47x | 1.31x |
| 52-Week HighHighest price in past year | $12.34 | $7.77 |
| 52-Week LowLowest price in past year | $3.00 | $2.19 |
| % of 52W HighCurrent price vs 52-week peak | +84.4% | +49.7% |
| RSI (14)Momentum oscillator 0–100 | 53.2 | 43.4 |
| Avg Volume (50D)Average daily shares traded | 735K | 3.5M |
Evenly matched — FDMT and RCKT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates FDMT as "Buy" and RCKT as "Buy". Consensus price targets imply 216.7% upside for FDMT (target: $33) vs 29.5% for RCKT (target: $5).
| Metric | FDMT4D Molecular Ther… | RCKTRocket Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $33.00 | $5.00 |
| # AnalystsCovering analysts | 14 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
FDMT leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best Overall4D Molecular Therapeutics, … (FDMT)Leads 4 of 6 categories
Loading custom metrics...
FDMT vs RCKT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is FDMT or RCKT a better buy right now?
Analysts rate 4D Molecular Therapeutics, Inc.
(FDMT) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FDMT or RCKT?
Over the past 5 years, 4D Molecular Therapeutics, Inc.
(FDMT) delivered a total return of -69. 0%, compared to -91. 1% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: FDMT returned -74. 3% versus RCKT's -90. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FDMT or RCKT?
By beta (market sensitivity over 5 years), Rocket Pharmaceuticals, Inc.
(RCKT) is the lower-risk stock at 1. 31β versus 4D Molecular Therapeutics, Inc. 's 1. 47β — meaning FDMT is approximately 12% more volatile than RCKT relative to the S&P 500. On balance sheet safety, 4D Molecular Therapeutics, Inc. (FDMT) carries a lower debt/equity ratio of 4% versus 9% for Rocket Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — FDMT or RCKT?
On earnings-per-share growth, the picture is similar: Rocket Pharmaceuticals, Inc.
grew EPS 26. 4% year-over-year, compared to 18. 8% for 4D Molecular Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — FDMT or RCKT?
Rocket Pharmaceuticals, Inc.
(RCKT) is the more profitable company, earning 0. 0% net margin versus -164. 4% for 4D Molecular Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCKT leads at 0. 0% versus -187. 2% for FDMT. At the gross margin level — before operating expenses — FDMT leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — FDMT or RCKT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is FDMT or RCKT better for a retirement portfolio?
For long-horizon retirement investors, Rocket Pharmaceuticals, Inc.
(RCKT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (RCKT: -90. 7%, FDMT: -74. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between FDMT and RCKT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FDMT is a small-cap high-growth stock; RCKT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.